SHANDONG XINHUA (00719) Receives Drug Registration Certificate for Sildenafil Citrate Orally Disintegrating Tablets

Stock News

Sep 16

SHANDONG XINHUA (00719) announced that it has recently received a Drug Registration Certificate for sildenafil citrate orally disintegrating tablets from the National Medical Products Administration.

In April 2024, Xinhua Pharmaceutical submitted registration application materials for the domestic production and marketing authorization of sildenafil citrate orally disintegrating tablets to the Center for Drug Evaluation (CDE) under the National Medical Products Administration, which was accepted for review. The company obtained the Drug Registration Certificate in September 2025, with the evaluation conclusion being approval for registration.

Sildenafil citrate orally disintegrating tablets are used for the treatment of erectile dysfunction. According to relevant statistical data, sales of sildenafil-related preparations in China's public medical institutions reached approximately RMB 5.2 billion in 2024.

Xinhua Pharmaceutical's receipt of the drug registration certificate for sildenafil citrate orally disintegrating tablets in September 2025 will be beneficial for the company to explore new market segments and enhance its market competitiveness.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1168601533"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1168601533\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1168601533?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-16 16:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1168601533","market":"sh","top_or_hot":-1,"title":"SHANDONG XINHUA (00719) Receives Drug Registration Certificate for Sildenafil Citrate Orally Disintegrating Tablets","media":"Stock News","content":"<p>SHANDONG XINHUA (00719) announced that it has recently received a Drug Registration Certificate for sildenafil citrate orally disintegrating tablets from the National Medical Products Administration.</p>\n<p>In April 2024, Xinhua Pharmaceutical submitted registration application materials for the domestic production and marketing authorization of sildenafil citrate orally disintegrating tablets to the Center for Drug Evaluation (CDE) under the National Medical Products Administration, which was accepted for review. The company obtained the Drug Registration Certificate in September 2025, with the evaluation conclusion being approval for registration.</p>\n<p>Sildenafil citrate orally disintegrating tablets are used for the treatment of erectile dysfunction. According to relevant statistical data, sales of sildenafil-related preparations in China's public medical institutions reached approximately RMB 5.2 billion in 2024.</p>\n<p>Xinhua Pharmaceutical's receipt of the drug registration certificate for sildenafil citrate orally disintegrating tablets in September 2025 will be beneficial for the company to explore new market segments and enhance its market competitiveness.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SHANDONG XINHUA (00719) Receives Drug Registration Certificate for Sildenafil Citrate Orally Disintegrating Tablets</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSHANDONG XINHUA (00719) Receives Drug Registration Certificate for Sildenafil Citrate Orally Disintegrating Tablets\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-09-16 16:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>SHANDONG XINHUA (00719) announced that it has recently received a Drug Registration Certificate for sildenafil citrate orally disintegrating tablets from the National Medical Products Administration.</p>\n<p>In April 2024, Xinhua Pharmaceutical submitted registration application materials for the domestic production and marketing authorization of sildenafil citrate orally disintegrating tablets to the Center for Drug Evaluation (CDE) under the National Medical Products Administration, which was accepted for review. The company obtained the Drug Registration Certificate in September 2025, with the evaluation conclusion being approval for registration.</p>\n<p>Sildenafil citrate orally disintegrating tablets are used for the treatment of erectile dysfunction. According to relevant statistical data, sales of sildenafil-related preparations in China's public medical institutions reached approximately RMB 5.2 billion in 2024.</p>\n<p>Xinhua Pharmaceutical's receipt of the drug registration certificate for sildenafil citrate orally disintegrating tablets in September 2025 will be beneficial for the company to explore new market segments and enhance its market competitiveness.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1515","symbol_name":"抗疫概念","start_time":0,"source_url":"","article_id":"1168601533","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1168601533","pubTimestamp":1758012748,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"SHANDONG XINHUA (00719) announced that it has recently received a Drug Registration Certificate for sildenafil citrate orally disintegrating tablets from the National Medical Products Administration....","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1515":"抗疫概念","00719":"山东新华制药股份","BK1191":"制药"},"translate_title":"山东新华(00719)获枸橼酸西地那非口腔崩解片药品注册证书","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00719":1},"content_text":"SHANDONG XINHUA (00719) announced that it has recently received a Drug Registration Certificate for sildenafil citrate orally disintegrating tablets from the National Medical Products Administration.\nIn April 2024, Xinhua Pharmaceutical submitted registration application materials for the domestic production and marketing authorization of sildenafil citrate orally disintegrating tablets to the Center for Drug Evaluation (CDE) under the National Medical Products Administration, which was accepted for review. The company obtained the Drug Registration Certificate in September 2025, with the evaluation conclusion being approval for registration.\nSildenafil citrate orally disintegrating tablets are used for the treatment of erectile dysfunction. According to relevant statistical data, sales of sildenafil-related preparations in China's public medical institutions reached approximately RMB 5.2 billion in 2024.\nXinhua Pharmaceutical's receipt of the drug registration certificate for sildenafil citrate orally disintegrating tablets in September 2025 will be beneficial for the company to explore new market segments and enhance its market competitiveness.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}